TWI798245B - 介白素-21突變蛋白及治療方法 - Google Patents

介白素-21突變蛋白及治療方法 Download PDF

Info

Publication number
TWI798245B
TWI798245B TW107127071A TW107127071A TWI798245B TW I798245 B TWI798245 B TW I798245B TW 107127071 A TW107127071 A TW 107127071A TW 107127071 A TW107127071 A TW 107127071A TW I798245 B TWI798245 B TW I798245B
Authority
TW
Taiwan
Prior art keywords
seq
mutein
heavy chain
amino acid
antibody
Prior art date
Application number
TW107127071A
Other languages
English (en)
Chinese (zh)
Other versions
TW201920239A (zh
Inventor
可哈里德 Ｍ Ｋ Ｚ 阿里
尼拉吉 加格底許 阿格沃
古南斯卡瑞恩 柯南
岸恩 福特茲
祖倫 王
達倫 貝茲
瑪麗莎 莫克
岳中俊介
Original Assignee
美商安進公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安進公司 filed Critical 美商安進公司
Publication of TW201920239A publication Critical patent/TW201920239A/zh
Application granted granted Critical
Publication of TWI798245B publication Critical patent/TWI798245B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW107127071A 2017-08-03 2018-08-03 介白素-21突變蛋白及治療方法 TWI798245B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762540692P 2017-08-03 2017-08-03
US62/540,692 2017-08-03
US201862616733P 2018-01-12 2018-01-12
US62/616,733 2018-01-12

Publications (2)

Publication Number Publication Date
TW201920239A TW201920239A (zh) 2019-06-01
TWI798245B true TWI798245B (zh) 2023-04-11

Family

ID=63350603

Family Applications (3)

Application Number Title Priority Date Filing Date
TW107127071A TWI798245B (zh) 2017-08-03 2018-08-03 介白素-21突變蛋白及治療方法
TW112109111A TWI901940B (zh) 2017-08-03 2018-08-03 介白素-21突變蛋白及治療方法
TW111130464A TWI844073B (zh) 2017-08-03 2018-08-03 介白素-21突變蛋白及治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW112109111A TWI901940B (zh) 2017-08-03 2018-08-03 介白素-21突變蛋白及治療方法
TW111130464A TWI844073B (zh) 2017-08-03 2018-08-03 介白素-21突變蛋白及治療方法

Country Status (37)

Country Link
US (2) US11541103B2 (enExample)
EP (2) EP3661954B1 (enExample)
JP (2) JP7079171B2 (enExample)
KR (2) KR20220092652A (enExample)
CN (2) CN118126157A (enExample)
AU (2) AU2018311079B2 (enExample)
BR (2) BR112020002013B1 (enExample)
CA (1) CA3071376A1 (enExample)
CL (3) CL2020000252A1 (enExample)
CO (1) CO2020001113A2 (enExample)
CR (1) CR20200099A (enExample)
CY (1) CY1125429T1 (enExample)
DK (1) DK3661954T3 (enExample)
ES (2) ES2975221T3 (enExample)
HR (1) HRP20220404T1 (enExample)
HU (1) HUE058233T2 (enExample)
IL (2) IL272137B2 (enExample)
JO (1) JOP20200020B1 (enExample)
LT (1) LT3661954T (enExample)
MA (1) MA56289B1 (enExample)
MX (2) MX2020001328A (enExample)
MY (1) MY195974A (enExample)
PE (2) PE20200867A1 (enExample)
PH (1) PH12020500231A1 (enExample)
PL (1) PL3661954T3 (enExample)
PT (1) PT3661954T (enExample)
RS (1) RS63101B1 (enExample)
SA (2) SA522432917B1 (enExample)
SG (1) SG11202000821SA (enExample)
SI (1) SI3661954T1 (enExample)
SM (1) SMT202200162T1 (enExample)
TN (1) TN2020000015A1 (enExample)
TW (3) TWI798245B (enExample)
UA (1) UA130113C2 (enExample)
UY (1) UY37829A (enExample)
WO (1) WO2019028316A1 (enExample)
ZA (2) ZA202001251B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11059892B2 (en) * 2017-08-11 2021-07-13 Research Development Foundation Engineered antibody Fc variants for enhanced serum half life
WO2019207942A1 (ja) * 2018-04-27 2019-10-31 OTA Takayo 免疫チェックポイント阻害剤によるがん治療の効果を評価するためのバイオマーカー
JP2021530243A (ja) * 2018-07-25 2021-11-11 アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. 新規ｉｌ−２１プロドラッグおよびそれを使用する方法
JP2022514702A (ja) * 2018-12-21 2022-02-14 オーエスイー・イミュノセラピューティクス 二機能性抗ｐｄ－１／ｉｌ－７分子
US12479909B2 (en) * 2019-02-22 2025-11-25 Anwita Biosciences, Inc. Albumin binding antibodies and use thereof
AU2020266560A1 (en) * 2019-04-30 2021-11-25 Absci Corporation Cancer associated antibody compositions and methods of use
US20220389119A1 (en) * 2019-11-08 2022-12-08 Amgen Inc. ENGINEERING CHARGE PAIR MUTATIONS FOR PAIRING OF HETERO-IgG MOLECULES
WO2021092719A1 (zh) * 2019-11-11 2021-05-20 王盛典 一种靶向抗原特异性t细胞诱导其向记忆干性细胞分化的融合蛋白
WO2021102063A1 (en) 2019-11-20 2021-05-27 Anwita Biosciences, Inc. Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications
CN111087473B (zh) * 2019-12-11 2022-06-14 上海百英生物科技有限公司 一种SIRPa-Fc-IL21融合蛋白及其应用
RS66193B1 (sr) 2020-05-26 2024-12-31 Boehringer Ingelheim Int Anti-pd-1 antitela
US20230257438A1 (en) * 2020-06-30 2023-08-17 Gi Innovation, Inc. Fusion protein comprising anti-lag-3 antibody and il-2, and use thereof
CN111925990B (zh) * 2020-09-02 2022-08-26 北京立康生命科技有限公司 一种针对卵巢癌的Anti-MUC16 CAR-T细胞及其制备方法
IL302276A (en) 2020-10-23 2023-06-01 Asher Biotherapeutics Inc Fusions with cd8 antigen binding molecules for modulating immune cell function
CA3199086A1 (en) * 2020-10-26 2022-05-05 Neptune Biosciences Llc Orthogonal il-21 receptor/cytokine systems
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
EP4259213A4 (en) * 2020-12-09 2024-11-20 Asher Biotherapeutics, Inc. TARGETED CYTOKINE CONSTRUCT FOR MANIPULATED CELL THERAPY
CN116744975A (zh) * 2020-12-23 2023-09-12 信达生物制药(苏州)有限公司 白细胞介素21突变体以及其用途
CN117321087A (zh) 2021-03-26 2023-12-29 先天制药公司 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
JP2024515263A (ja) * 2021-04-09 2024-04-08 オーエスイー・イミュノセラピューティクス 改善された特性を有する二機能性分子のための新規足場構造
TW202309081A (zh) 2021-04-27 2023-03-01 美商安進公司 藉由使用溫度調節不對稱多特異性抗體之產物品質
JP2024522069A (ja) 2021-05-19 2024-06-11 アシャ バイオセラピューティクス，インク． Ｉｌ－２１ポリペプチド及び標的化コンストラクト
MX2023014647A (es) 2021-06-09 2024-01-31 Innate Pharma Proteinas de union a nkp46 multiespecificas.
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CA3227990A1 (en) * 2021-08-06 2023-02-09 Amgen Inc. Isolation of therapeutic protein
WO2023048516A1 (ko) * 2021-09-24 2023-03-30 바이오엔시스템스 주식회사 Pd-1 및 il-21을 포함하는 융합단백질 이량체 및 이의 용도
CA3234007A1 (en) * 2021-09-30 2023-04-06 Yunovia Co., Ltd. Immunocytokine containing il-21r mutein
WO2023205738A2 (en) * 2022-04-20 2023-10-26 Neptune Biosciences Llc Orthogonal il-21 receptor/cytokine systems
CA3255321A1 (en) * 2022-05-05 2023-11-09 Amgen Research (Munich) Gmbh HETEROMULTIMER BINDING TO DLL3 AND CD3
KR102796245B1 (ko) * 2022-05-10 2025-04-18 아주대학교산학협력단 인터루킨21 변이체, 이를 포함하는 융합단백질 및 이의 용도
JP2025521518A (ja) * 2022-06-29 2025-07-10 ベイジン ネオエックス バイオテック リミテッド Ｉｌ－２１ポリペプチドおよび使用方法
CN117645669B (zh) * 2022-08-29 2024-11-01 星奕昂(上海)生物科技有限公司 具有膜结合型il-21的免疫细胞及其制法和应用
CN117645661A (zh) * 2022-09-02 2024-03-05 北京志道生物科技有限公司 一种聚乙二醇修饰的il-21衍生物及其应用
WO2024228173A2 (en) * 2023-05-04 2024-11-07 Peptone, Ltd. Engineered cytokines and uses thereof
WO2025191133A1 (en) * 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191139A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of her2-specific antigen binding proteins and cytokines
EP4644413A1 (en) * 2024-05-03 2025-11-05 Genmab B.V. Binding agents having altered fc-mediated effector functions
WO2025251226A1 (en) 2024-06-05 2025-12-11 Nuwacell Biotechnologies Co., Ltd. Use of interleukin-21 and interleukin-15 for enhancing serial killing of natural killer cell for cell therapy against target cell
WO2026003219A1 (en) * 2024-06-26 2026-01-02 Anaveon AG Proximity activated interleukin 21
EP4671273A1 (en) * 2024-06-26 2025-12-31 Anaveon AG INTERLEUKIN 21 PROXIMITY ACTIVATED
CN118546233B (zh) * 2024-07-30 2024-10-18 成都微芯新域生物技术有限公司 白介素-21突变体及其应用
CN119954929B (zh) * 2025-02-12 2025-12-02 华润生物医药有限公司 Il-21突变体、含其的融合蛋白、核酸、重组表达载体、宿主细胞及其制备方法和用途
CN119954928B (zh) * 2025-02-12 2025-12-02 华润生物医药有限公司 Il-21突变体、含其的融合蛋白、核酸、重组表达载体、宿主细胞及其制备方法和用途
CN119978098A (zh) * 2025-02-12 2025-05-13 华润生物医药有限公司 Il-21突变体、含其的融合蛋白、核酸、重组表达载体、宿主细胞及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013169693A1 (en) * 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US6303144B1 (en) 1998-02-10 2001-10-16 Welfide Corporation Preparations with controlled release
NZ507381A (en) 1998-04-21 2003-12-19 Micromet Ag CD19xCD3 specific polypeptides and uses thereof
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2000040734A1 (en) 1998-12-31 2000-07-13 Arch Development Corporation Recombinant herpes simplex virus useful for treating neoplastic disease
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2000054795A1 (en) 1999-03-15 2000-09-21 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6764675B1 (en) 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
BR0107736A (pt) 2000-01-21 2002-11-19 Biovex Ltd Uso de uma cepa de vìrus não laboratorial, métodos para determinar se um gene tem um efeito sobre um fenótipo associado com um distúrbio dos sistemas nervosos periférico e central ou sobre uma célula dos sistemas nervosos periférico e central, para determinar se um gene codifica um antìgeno associado com uma infecção patogênica ou câncer, para determinar a adequabilidade de uma cepa de vìrus não laboratorial para modificação em uma cepa modificada, para determinar se um gene aumenta os efeitos anti-tumorais de um vìrus e para produzir uma cepa de vìrus não laboratorial oncolìtica, modificada, cepa de vìrus não laboratorial, uso de um gene, cepa hsv1 js1, composição farmacêutica, e, métodos para tratar um tumor em um indivìduo, para suprir um gene a um indivìduo e para tratar ou impedir um distúrbio do sistemas nervosos periférico e central
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US7749745B2 (en) 2001-03-27 2010-07-06 Georgetown University Viral vectors and their use in therapeutic methods
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
WO2003040313A2 (en) 2001-11-05 2003-05-15 Zymogenetics, Inc Il-21 antagonists
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
AU2003280410B8 (en) 2002-01-18 2009-04-23 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
US7736652B2 (en) 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
US20040009150A1 (en) 2002-06-07 2004-01-15 Nelson Andrew J. Methods of treating cancer using IL-21
WO2004033036A2 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
CN1513993A (zh) * 2002-12-31 2004-07-21 北京博泰迪生物工程科技开发有限公司 中国人基因组cDNA文库白细胞介素21的编码基因序列及其蛋白质的氨基酸序列
WO2004106381A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
WO2005030196A2 (en) 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using il-21
HRP20110187T1 (hr) 2003-10-16 2011-04-30 Micromet Ag Multispecifične deimunizirane tvari koje vežu cd3
MXPA06014075A (es) 2004-06-03 2007-03-15 Novimmune Sa Anticuerpos anti-cd3 y metodos de uso de los mismos.
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
CA2599925A1 (en) 2005-03-14 2006-09-21 Merck & Co., Inc. Cgrp receptor antagonists
MX2007012887A (es) 2005-04-18 2007-12-10 Novo Nordisk As Variantes il-21.
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
AU2006341398B9 (en) 2005-11-28 2012-02-02 Zymogenetics, Inc. IL-21 receptor antagonists
EP2567973B1 (en) 2005-11-28 2014-05-14 Zymogenetics, Inc. IL-21 antagonists
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
WO2007128563A1 (en) 2006-05-08 2007-11-15 Philogen Spa Antibody-targeted cytokines for therapy
JP2010507382A (ja) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
WO2008074863A1 (en) 2006-12-21 2008-06-26 Novo Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
CN101230334B (zh) 2007-01-22 2011-06-01 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
CN101230335B (zh) 2007-01-22 2010-08-11 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
EP2155783B2 (en) 2007-04-03 2022-10-19 Amgen Research (Munich) GmbH Cross-species-specific cd3-epsilon binding domain
AU2008234020B2 (en) 2007-04-03 2013-02-07 Amgen Research (Munich) Gmbh Cross-species-specific CD3-epsilon binding domain
CA2683698C (en) 2007-04-19 2013-09-10 Hyun Hee Kwak A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
US7883700B2 (en) 2007-12-07 2011-02-08 Zymogenetics, Inc. Anti-human IL-21 monoclonal antibodies
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
HRP20160684T1 (hr) 2008-10-01 2016-07-15 Amgen Research (Munich) Gmbh Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću
WO2010103038A1 (en) * 2009-03-11 2010-09-16 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
KR102010827B1 (ko) 2009-06-26 2019-08-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
AR077879A1 (es) 2009-08-17 2011-09-28 Roche Glycart Ag Inmunoconjugados dirigidos
RU2607374C2 (ru) 2009-10-30 2017-01-10 Новозаймс Байофарма Дк А/С Варианты альбумина
EP3798237A1 (en) 2010-03-05 2021-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
EP2635598A1 (en) 2010-11-01 2013-09-11 Novozymes Biopharma DK A/S Albumin variants
BR112013019083A2 (pt) 2011-02-10 2017-04-04 Roche Glycart Ag combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença.
WO2012125495A2 (en) 2011-03-11 2012-09-20 Amgen Inc. Method of correlated mutational analysis to improve therapeutic antibodies
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
MX353816B (es) 2011-05-05 2018-01-30 Albumedix As Variantes de albumina.
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US20130028882A1 (en) 2011-07-07 2013-01-31 Humanitas Technology, LLC Antiviral compositions and methods of their use
ES2704632T3 (es) 2011-09-08 2019-03-19 Univ New York Virus de herpes simplex oncolítico y sus usos terapéuticos
EA034989B1 (ru) * 2011-10-28 2020-04-15 Тева Фармасьютикал Австралия Пти Лтд Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
US20150030562A1 (en) 2011-12-23 2015-01-29 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Methods of treating or preventing viral diseases by blocking interleukin-21
WO2013109904A1 (en) 2012-01-19 2013-07-25 University Of Miami Compositions, methods and kits for treatment of cancer and autoimmune diseases
PL2825556T3 (pl) 2012-03-16 2018-10-31 Albumedix A/S Warianty albuminy
CA2947354C (en) 2012-04-30 2024-03-19 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
US9441039B2 (en) 2012-05-07 2016-09-13 Amgen Inc. Anti-erythropoietin antibodies
EP3434695B1 (en) 2012-08-07 2020-12-02 Roche Glycart AG Improved immunotherapy
AU2013343503B2 (en) 2012-11-08 2017-12-14 Albumedix Ltd. Albumin variants
WO2014139468A1 (en) 2013-03-15 2014-09-18 Admark Healthcare, Llc Fusion protein molecules and method of use
ES2845609T3 (es) 2013-05-02 2021-07-27 Anaptysbio Inc Anticuerpos dirigidos contra muerte programada-1 (PD-1)
WO2015000585A1 (en) * 2013-07-02 2015-01-08 Walter Sebald Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
ES2780948T3 (es) 2013-07-11 2020-08-27 Scripps Research Inst Proteínas de fusión de inmunoglobulinas en hélice enrollada y composiciones de las mismas
SI3081576T1 (sl) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015117930A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
WO2015124297A1 (en) 2014-02-19 2015-08-27 Merck Patent Gmbh Cancer-targeted il-12 immunotherapy
WO2015157238A2 (en) 2014-04-08 2015-10-15 Medimmune, Llc Binding molecules specific for il-21 and uses thereof
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
WO2016100375A2 (en) 2014-12-15 2016-06-23 Washington University Compositions and methods for targeted cytokine delivery
US10940212B2 (en) 2014-12-19 2021-03-09 Monash University IL-21 agonist antibodies and methods of treatment using same
EP3233914A1 (en) 2014-12-19 2017-10-25 Mabtech Ab Composition, kit and method for inhibition of il-21 mediated activation of human cells
KR20160113452A (ko) 2015-03-20 2016-09-29 (주)엘지하우시스 진공 단열재용 심재 및 진공단열재
KR102761886B1 (ko) 2015-07-30 2025-02-06 마크로제닉스, 인크. Pd-1-결합 분자 및 그것의 사용 방법
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
WO2017023779A1 (en) 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
PL3334763T3 (pl) 2015-08-11 2024-12-02 WuXi Biologics Ireland Limited Nowe przeciwciała anty-pd-1
MA48579A (fr) 2015-09-01 2020-03-18 Agenus Inc Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
ES2895034T3 (es) 2015-10-02 2022-02-17 Hoffmann La Roche Anticuerpos anti-PD1 y procedimientos de uso
DK3370768T3 (da) 2015-11-03 2022-03-21 Janssen Biotech Inc Antistoffer som specifikt binder pd-1 og anvendelser deraf
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
BR112018012801B1 (pt) * 2015-12-22 2024-03-12 Regeneron Pharmaceuticals, Inc Usos de uma combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 e de uma composição farmacêutica
MX2018008413A (es) 2016-01-08 2019-02-20 Replimune Ltd Virus oncolitico modificado.
EP3402508A4 (en) 2016-01-11 2019-09-25 Flagship Pioneering Innovations V, Inc. METHOD AND COMPOSITIONS FOR MODULATING THE THYMUS FUNCTION
CN114716557A (zh) 2016-02-03 2022-07-08 安进研发（慕尼黑）股份有限公司 Psma和cd3双特异性t细胞接合抗体构建体
CN116063544A (zh) 2016-02-03 2023-05-05 安进研发（慕尼黑）股份有限公司 Bcma和cd3双特异性t细胞接合抗体构建体
CA3013558C (en) 2016-02-05 2024-11-12 Universiteit Gent CD8 LIAISON OFFICERS
US11053293B2 (en) 2016-02-05 2021-07-06 Washington University Compositions and methods for targeted cytokine delivery
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
JP7082604B2 (ja) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
WO2017173410A1 (en) 2016-04-01 2017-10-05 Amgen Inc. Chimeric receptors to flt3 and methods of use thereof
KR102323872B1 (ko) 2016-04-22 2021-11-08 임비라 컴퍼니 리미티드 암치료용 종양 용해성 단순 헤르페스 바이러스(oHSV) 절대 벡터 및 그 구조체의 구조
RU2021127872A (ru) 2016-06-30 2021-11-09 Онкорус, Инк. Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
RU2656181C1 (ru) 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
WO2018026872A1 (en) 2016-08-01 2018-02-08 Virogin Biotech Canada Ltd Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
KR101928981B1 (ko) 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
PE20191076A1 (es) 2016-09-14 2019-08-20 Beijing hanmi pharm co ltd Anticuerpo que se une especificamente a pd-1 y fragmento funcional del mismo
FI3515938T3 (fi) 2016-09-21 2025-03-27 Cstone Pharmaceuticals Monoklonaallisia vasta-aineita ohjelmoituun kuolemaan (PD-1)
WO2018057943A1 (en) 2016-09-23 2018-03-29 Oncosec Medical Incorporated Modulating responses to checkpoint inhibitor therapy
KR20190088480A (ko) 2016-11-02 2019-07-26 조운스 테라퓨틱스, 인크. Pd-1에 대한 항체 및 그의 용도
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CN107082812B (zh) 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
MX2019011770A (es) 2017-04-03 2020-01-09 Hoffmann La Roche Inmunoconjugados de un anticuerpo anti-pd-1 con un mutante il-2 o con il-15.
US11471490B2 (en) 2017-07-03 2022-10-18 Torque Therapeutics, Inc. T cells surface-loaded with immunostimulatory fusion molecules and uses thereof
US20210260163A1 (en) 2018-03-09 2021-08-26 AskGene Pharma, Inc. Novel cytokine prodrugs
CN112512551A (zh) 2018-03-28 2021-03-16 奥里尼斯生物科学公司股份有限公司 双功能蛋白及其构建
JP7479290B2 (ja) 2018-04-10 2024-05-08 アムジエン・インコーポレーテツド Ｄｌｌ３に対するキメラ受容体及びその使用方法
US12091438B2 (en) 2018-06-18 2024-09-17 Anwita Biosciences, Inc. Anti-mesothelin constructs and uses thereof
JP2022502443A (ja) 2018-09-28 2022-01-11 ピエール、ファーブル、メディカマン 癌の処置のための新規な免疫サイトカイン
WO2020127369A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013169693A1 (en) * 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Maria Jure-Kunkel et al., "Nonclinical evaluation of the combination of mouse IL-21 and anti- mouse CTLA-4 or PD-1 blocking antibodies in mouse tumor models." Journal of Clinical Oncology 31, no. 15_suppl., American Society of Clinical Oncology, May 20 2013, p. 3019-3019. *

Also Published As

Publication number Publication date
SA520411230B1 (ar) 2022-11-08
BR112020002013B1 (pt) 2023-01-24
PE20250757A1 (es) 2025-03-13
PH12020500231A1 (en) 2021-01-11
MA56289B1 (fr) 2022-04-29
ES2910969T3 (es) 2022-05-17
PE20200867A1 (es) 2020-08-31
LT3661954T (lt) 2022-04-11
AU2022228122B2 (en) 2024-05-02
JP2022116099A (ja) 2022-08-09
MX2023013462A (es) 2023-12-15
IL272137B2 (en) 2024-11-01
IL312607A (en) 2024-07-01
JOP20200020B1 (ar) 2023-09-17
HUE058233T2 (hu) 2022-07-28
DK3661954T3 (da) 2022-04-19
JOP20200020A1 (ar) 2020-02-02
IL312607B2 (en) 2025-08-01
KR20200035291A (ko) 2020-04-02
SMT202200162T1 (it) 2022-05-12
RS63101B1 (sr) 2022-04-29
CR20200099A (es) 2020-07-24
SI3661954T1 (sl) 2022-05-31
CN111164100A (zh) 2020-05-15
EP4029877B1 (en) 2024-01-17
ZA202210065B (en) 2025-04-30
CL2020000252A1 (es) 2020-08-21
CN111164100B (zh) 2024-03-12
MY195974A (en) 2023-02-27
ES2975221T3 (es) 2024-07-04
JP7531545B2 (ja) 2024-08-09
AU2022228122A1 (en) 2022-09-29
WO2019028316A1 (en) 2019-02-07
UA130113C2 (uk) 2025-11-19
KR102414120B1 (ko) 2022-06-28
CL2022000300A1 (es) 2022-09-23
IL272137A (en) 2020-03-31
TWI901940B (zh) 2025-10-21
AU2018311079A1 (en) 2020-02-13
JP2019033743A (ja) 2019-03-07
KR20220092652A (ko) 2022-07-01
CO2020001113A2 (es) 2020-05-15
US11541103B2 (en) 2023-01-03
CL2024002249A1 (es) 2025-02-21
JP7079171B2 (ja) 2022-06-01
SG11202000821SA (en) 2020-02-27
EP3661954A1 (en) 2020-06-10
ZA202001251B (en) 2025-04-30
IL272137B1 (en) 2024-07-01
CN118126157A (zh) 2024-06-04
EP3661954B1 (en) 2022-02-09
EP4029877A1 (en) 2022-07-20
US20230381276A1 (en) 2023-11-30
MX2020001328A (es) 2020-03-20
AU2018311079B2 (en) 2022-06-23
SA522432917B1 (ar) 2023-11-05
TW202246308A (zh) 2022-12-01
CY1125429T1 (el) 2024-02-16
TW201920239A (zh) 2019-06-01
HRP20220404T1 (hr) 2022-05-27
PL3661954T3 (pl) 2022-05-16
UY37829A (es) 2019-01-31
TWI844073B (zh) 2024-06-01
MA56289A (fr) 2020-06-10
BR122021015266B1 (pt) 2023-01-24
US20190046611A1 (en) 2019-02-14
CA3071376A1 (en) 2019-02-07
TW202342501A (zh) 2023-11-01
BR112020002013A2 (pt) 2020-07-28
TN2020000015A1 (en) 2021-10-04
IL312607B1 (en) 2025-04-01
PT3661954T (pt) 2022-04-14

Similar Documents

Publication Publication Date Title
TWI798245B (zh) 介白素-21突變蛋白及治療方法
US11518808B2 (en) Anti-PD-1 antibodies and methods of treatment
HK40076582A (en) Interleukin-21 muteins and methods of treatment
HK40076582B (en) Interleukin-21 muteins and methods of treatment
HK40029717A (en) Interleukin-21 muteins and methods of treatment
HK40029717B (en) Interleukin-21 muteins and methods of treatment
HK40037194B (en) Anti-pd-1 antibodies and methods of treatment
HK40037194A (en) Anti-pd-1 antibodies and methods of treatment